Québec City, Québec – March 10, 2016 – TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, has been invited to present at the 28th Annual ROTH Capital Partners Conference, which is being held on March 14-16, 2016 at The Ritz-Carlton, Laguna Niguel in Dana Point, California.
TSO3 CFO Glen Kayll is scheduled to present on Wednesday, March 16, 2016, at 8:00 a.m. Pacific time. He will participate in one-on-one meetings held on March 15-16, 2016.
Kayll will discuss the company’s business, including its activities in response to recently announced orders for its STERIZONE® VP4 Sterilizer and related accessories placed by Getinge Infection Control, its global distribution partner.
For more information about the conference or to schedule a one-on-one meeting with TSO3 management, please contact your ROTH representative at 1-800-933-6830 or via e-mail at email@example.com.
Founded in 1998, TSO3’s activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.
For more information about TSO3, visit the company’s web site at www.tso3.com or contact Liolios Group at 949 574-3860 or email TOS@liolios.com or Renmark Financial Communications at 416 644-2020 or 514 939-3989 or by email at firstname.lastname@example.org.
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
– 30 –Back to Posts